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Abstract
Background: Dexamethasone suppressed inflammation and haemodynamic changes in an animal model of
pulmonary arterial hypertension (PAH). A major target for dexamethasone actions is NF-κB, which is activated in
pulmonary vascular cells and perivascular inflammatory cells in PAH. Reverse remodelling is an important concept
in PAH disease therapy, and further to its anti-proliferative effects, we sought to explore whether dexamethasone
augments pulmonary arterial smooth muscle cell (PASMC) apoptosis.
Methods: Analysis of apoptosis markers (caspase 3, in-situ DNA fragmentation) and NF-κB (p65 and phospho-IKK-α/β)
activation was performed on lung tissue from rats with monocrotaline (MCT)-induced pulmonary hypertension (PH),
before and after day 14–28 treatment with dexamethasone (5 mg/kg/day). PASMC were cultured from this rat PH model
and from normal human lung following lung cancer surgery. Following stimulation with TNF-α (10 ng/ml), the effects of
dexamethasone (10−8–10−6 M) and IKK2 (NF-κB) inhibition (AS602868, 0–3 μM (0-3×10−6 M) on IL-6 and CXCL8 release
and apoptosis was determined by ELISA and by Hoechst staining. NF-κB activation was measured by TransAm assay.
Results: Dexamethasone treatment of rats with MCT-induced PH in vivo led to PASMC apoptosis as displayed by
increased caspase 3 expression and DNA fragmentation. A similar effect was seen in vitro using TNF-α-simulated human
and rat PASMC following both dexamethasone and IKK2 inhibition. Increased apoptosis was associated with a reduction
in NF-κB activation and in IL-6 and CXCL8 release from PASMC.
Conclusions: Dexamethasone exerted reverse-remodelling effects by augmenting apoptosis and reversing inflammation
in PASMC possibly via inhibition of NF-κB. Future PAH therapies may involve targeting these important inflammatory
pathways.
Introduction
Pulmonary arterial hypertension (PAH) is an incurable
condition associated with remodelling of resistance, pre-
capillary pulmonary arterioles, subsequent right ven-
tricular failure and premature death. Despite recent
advances in the understanding of underlying genetic sus-
ceptibility of PAH, the exact underlying pathogenesis is
unknown and the condition remains incurable. Recent
evidence suggests that inflammation plays an important
role in the pathogenesis of both animal models of PH
and human PAH (including idiopathic PAH) [1–7]. As
such, concentrations of circulating cytokines, such as IL-
6, are raised in patients with idiopathic PAH and are of
prognostic importance [8, 9]. Furthermore, perivascular
inflammatory cells are observed in post-mortem and
post-transplant histological specimens [10–12] and there
appears to be dysregulation of circulating inflammatory
cells [13]. In support of continuing inflammation being
important we have recently demonstrated up-regulation
of NF-κB signalling in endothelial cells, smooth muscle
cells, macrophages and lymphocytes in histological sec-
tions from patients with idiopathic PAH [5].
However, convincing evidence for anti-inflammatory or
immunosuppressive therapy working in patients with PAH
exists only in a minority: patients with mixed connective
tissue disease, systemic lupus erythematosus, Castleman’s
disease and Polyneuropathy, Organomegaly, Endocrinopa-
thy, Monoclonal gammopathy and Skin abnormalities
(POEMS) Syndrome [14–17]. Immunosuppressive therapy
does not appear to be effective in scleroderma PAH [16].
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To our knowledge immunosuppressive therapy has not
been formally tested in patients with idiopathic PAH,
although cases have been reported [18].
We have recently demonstrated that the glucocorticoid
(GC) dexamethasone was able to prevent and reverse
pulmonary vascular remodelling associated with the
monocrotaline (MCT) model of pulmonary hypertension
[19]. Dexamethasone also prevented and reversed the se-
vere pulmonary haemodynamics associated with this
model of pulmonary hypertension [19]. Furthermore, we
were able to show that dexamethasone inhibited prolif-
eration of pulmonary arterial smooth muscle cells
(PASMC) isolated from this model [19]. In an isolated
report, prednisolone appeared to inhibit proliferation of
PASMC from patients with idiopathic PAH, associated
with a reduction in cell cycle markers [20]. However, in-
hibition of proliferation does not explain the reversal of
remodelling we observed in the MCT model of PH and
would not provide the optimal potential therapy for pa-
tients who are likely to have significant remodelling of
their pulmonary vasculature at diagnosis. As such we
sought to investigate the mechanisms by which GCs re-
verse remodelling in the MCT model of PH. Under-
standing such mechanisms may provide novel and more
effective treatments for the future.
Materials and methods
In situ DNA fragmentation assay
In situ DNA fragmentation was performed on paraffin
lung sections using a VasoTACS kit (R&D systems) ac-
cording to Manufacturer’s instructions. The TACS-XL
assay uses Terminal deoxynucleotidyl Transferase (TdT)
to incorporate nucleotides into the 3′-OH ends of DNA
fragments. These nucleotides are BrdU-labeled and a bi-
otinylated anti-BrdU antibody is then used for detection.
Rat lung immunohistochemistry
Rat lung Paraffin sections (5 μm thick) were obtained
following in vivo experiments as previously described
[19]. Sections were incubated with peroxidase blocking
solution (Dako, Cambridge) and then with primary anti-
bodies for rabbit anti-active caspase-3 (1:50 Abcam
ab2302), NF-κB p65 (1:200 Cell Signaling C22B4), rabbit
anti-phospho-IKKα/β (1:40 Cell Signaling 2697), P-Stat3
(1:50 Cell Signalling 9145); Stat3 (1:400 Cell Signalling
9149) or SMA (1:400 Dako M0851). Sections were then
incubated with polyclonal goat anti-rabbit horseradish
peroxidase (HRP)-conjugated secondary antibody (Dako)
followed by incubation with diaminobenzidine (DAB)
and peroxide buffer (Sigma) to produce a brown stain.
Slides were counterstained with hematoxylin or eosin to
provide nuclear and morphological detail. Non- specific
rabbit IgG (Sigma-Aldrich) at the same concentration as
those used above was used as a control.
Immunohistochemical scoring
Slides were numbered and coded and performed by two
blinded assessors. Cells within pulmonary vessels were
identified using light microscopy. Standard morphomet-
ric end points were also measured. At least 10 sections
per subject were analyzed. For apoptosis, the percentage
(e.g. for caspase-3) of pulmonary arterial smooth muscle
cells (PASMC) staining positive was determined over the
total number of cells counted.
Pulmonary arterial smooth muscle cell isolation and
culture
PASMCs were isolated from control and monocrotaline
(MCT)-exposed rats and from normal human lung ex-
cised from patients undergoing surgery for lung cancer
as previously described [19, 21]. For the MCT model,
male 6-week old Wistar rats (100 g body weight) were
maintained in a temperature-controlled room with a
12:12-h light–dark cycle with access to standard rat
chow and water. Rats received a standard single subcuta-
neous injection of 60 mg/kg monocrotaline (MCT)
(Sigma-Aldrich, Lyon, France) [19]. Rat PASMCs were
maintained in DMEM containing 10 % FCS and used
from passage 3–6. Human PASMCs were maintained in
DMEM containing 15 % FCS and used from passage 3–8.
Hoechst 33342 staining
Rat and human PASMCs were plated at a seeding dens-
ity of 2.5×104 cells/well in 8-well Lab-Tek slides. Cells
were starved for 24 h and then treated with various
concentrations of dexamethasone or IKK-2 inhibitor
(AS602868, kindly provided by Serono International SA,
Geneva, Switzerland) for 24, 48 and 72 h in DMEM
without FCS. After treatment, cells were fixed and
mounted with solution containing 5 μg/ml Hoechst
33342. Images (3–5 non-overlapping randomly selected
fields for each well) were taken using a Zeiss fluores-
cence Microscope. The number of apoptotic cells exhi-
biting condensed nuclear fluorescence was determined
and expressed as a proportion of the total cells.
ELISA for DNA fragmentation
The Cell Death Detection ELISA Plus kit (Roche
Applied Science, Indianapolis, USA) was used to detect
cytoplasmic histone-associated-DNA fragments. PASMC
were plated at 5×104 cells per well in 24-well plates and
treated as described above. After treatment, cells were
lysed with lysis buffer. ELISA was performed accord-
ing to manufacturer’s instruction. The samples are
placed into a streptavidin-coated microplate and
incubated with a mixture of anti-histone-biotin and anti-
DNA-peroxidase. Nucleosomes are captured via their
histone component whilst anti-DNA-peroxidase binds to
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the DNA part of the nucleosomes. After removal of the
unbound antibodies, the amount of peroxidase retained in
the immunocomplex is photometrically determined with
ABTS as the substrate. This allows the specific
determination of mono- and oligonucleosomes in the
cytoplasmic fraction of cell lysates.
Measurement of cytokine release from human PASMC
Human PASMC were plated in 96-well plates (5000
cells/well) and cultured in DMEM/15 % FCS until 90 %
confluent; cells were serum-starved overnight and then
tumour necrosis factor (TNF)-α (10 ng/ml) for 24 h
used as the stimulus in the presence or absence of dexa-
methasone (10−8–10−6 M) or an IKK-2 inhibitor
(AS602868, 0–3 μM). After 24 h, the supernatant was
aspirated and stored at −20 °C and MTT viability assays
(Sigma Aldrich) were performed. ELISA measurement of
IL-6 and CXCL8 levels (Human ELISA DuoSet, R&D
Systems) were performed on supernatants according to
the manufacturer’s instructions as follows using distinct
capture and detection antibodies: 100 μl of assay diluent,
50 μl of standard or cell culture supernatants were pipet-
ted to each well sequentially, and incubated at room
temperature for 2 h. After incubation, wells were washed
4 times and incubated with 100 μl of conjugate for 1 h.
Wells were then washed 4 times and incubated with
200 μl of substrate solution for 30 min. The plates were
read at 450 nm using a BioTek plate reader immediately
after 50 μl of stop solution was pipetted to each well.
Western blot analysis
150 mg of rat lung tissue from each animal was cut into
1 mm3 size pierces and put into a CK14 Precellys Lysing
kit (Stretton Scientific), 150 μl 2× cell lysis buffer (Cell
signaling) was then added to each tube, tissue lysis was
performed using Precellys 24 (Stretton Scientific) pro-
gram 1 (5100 rpm 2×15s pause 20 s). Samples were then
centrifuged at 13000 rpm for 1 min; supernatants were
centrifuged again at 13000 rpm for 10 min. 40 μg of
total protein from each sample was separated on SDS-
PAGE and transferred to nitrocellulose membranes or
polyvinylidene fluoride membranes (GE Healthcare).
Membranes were probed with anti- activated caspase 3,
and GAPDH (Cell Signaling). Membranes were devel-
oped using ECL (GE Healthcare). The intensity of the
bands was quantified using Image J (NIH).
Measurement of activation of NF-κB
Tissue preparation and nuclear extraction
Human PASMC (1x106 cells) were plated in 10 cm cell
culture dishes overnight and then starved for 24 h. After
starvation, cells were treated with TNF-α (0–10 ng/ml)
in the presence or absence of dexamethasone (10−7 M)
for 24 h. Cells were then collected and resuspended in
100 μl of 1X hypotonic buffer and incubated on ice for
15 min. After incubation, 5 μl detergent was pipetted to
cell suspension and vortex 10 s at the highest setting.
Cell suspensions were then centrifuged at 14,000 × g for
30 s at 4 °C and supernatants were removed. The pellets
(nuclears) were resuspended in 50 μl of complete lysis
buffer and incubate on ice for 30 min. Nuclear suspen-
sions were vortex for 30 s at the highest setting before
centrifugation at 14,000 x g for 10 min (Active Motif,
Rixensart, Belgium). The protein contents in the super-
natants (nuclear extracts) were estimated using Bradford
assay and then frozen at −80 °C.
NF-κB transcription factor p65 TransAM assay
This was performed on nuclear extracts using the p65
TransAM® Kit (Active Motif ) according to the manufac-
turer’s instructions. The TransAM assay has an NF-κB
consensus-binding site oligonucleotide immobilized to a
96 well plate. Nuclear extract is added to each well and
activated NF-κB binds specifically to the bound oligo-
nucleotide. This is detected using an anti-p65 subunit
antibody specific for an epitope on the bound and active
form of p65. Subsequent incubation with a secondary
antibody and developing agent enables quantification.
Statistical methods
Data are presented as mean and standard error of the
mean (SEM). For each dataset the normality of distribu-
tion was determined using the Kolmogorov-Smirnov
test. Single comparisons were made using Students t-test,
and multiple comparisons tested using one-way ANOVA,
followed by appropriate post-tests. Differences at a p < 0.05
were considered significant. Statistical analysis used Prism
version 5.0 (GraphPad software, La Jolla, CA, USA).
Results
Effects of dexamethasone on rat PASMC apoptosis:
immunohistochemical analysis
Immunohistochemical analysis of rat lung demonstrated
an increase in caspase-3 immunostaining (solid arrow)
within the PASMC layer in dexamethasone-treated
MCT rats at day 28 compared to untreated MCT controls
(caspase-3-negative PASMC, unfilled arrows, Fig. 1a–c).
When assessed by morphometric scoring, there was a
significant increase in caspase-3-positive PASMC stain-
ing in the dexamethasone-treated MCT group compared
to the untreated MCT group (8.4 ± 4.3 vs. 54.8 ± 5.9 %,
p < 0.0001) (Fig. 1e–f ). This observation was further
confirmed by Western blot analysis for caspase 3 in
whole lung protein extracts followed by densitom-
etry analysis (Fig. 1g–h).
Further, in-situ DNA fragmentation assay showed that
the percentage of PASMC scoring positive (an increase blue
nuclear staining) increased. Blinded morphometric scoring
Price et al. Respiratory Research  (2015) 16:114 Page 3 of 16
A B
C D
E
G
H
F
Fig. 1 (See legend on next page.)
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in lung sections from rats showed that apoptosis was in-
creased in MCT-treated controls compared to untreated
rats (5.3 ± 2.8 vs. 38.8 ± 6.1, p < 0.001) (Fig. 2a, c, e) and was
further increased in dexamethasone-treated MCT-exposed
rats (38.8 ± 6.1 vs. 59.9 ± 3.9, p < 0.05) (Fig. 2c, d, e).
Effects of dexamethasone on rat PASMC apoptosis: in
vitro analysis
Serum withdrawal (0 % FCS) induced a characteristic
apoptotic response in PASMC, as demonstrated by
nuclear condensation with Hoechst 33342 staining (Fig. 3).
(See figure on previous page.)
Fig. 1 Dexamethasone increases caspase-3 immunohistochemistry scores in rat pulmonary artery smooth muscle cells (PASMC) in vivo. Caspase-3
immunostaining was performed on rat lung resected at day 28 in (a) control rats showing caspase-negative PASMC (unfilled arrow) (magnification ×100),
(b) monocrotaline (MCT)-treated rats showing caspase-negative PASMC (unfilled arrow) (b) and (c) (B and C, magnification ×200), MCT+ dexamethasone
(5 mg/kg/day, days 14–28)-treated rats showing caspase-positive PASMC (filled arrow). Images are representative of n= 5 per group. Antibody-negative
staining controls are shown in an untreated control rat (d, magnification ×100). Caspase-3 immunohistochemistry scoring was performed by an assessor
blinded to the groups and presented as (e) percentage of caspase-3 positive PASMC over total PASMC and (f) the numbers of caspase-3-positive PASMC
per mm2. Western blot analysis of cleaved caspase 3 in 3 independent lung samples from control untreated, MCT-treated and MCT + dexamethasone
(MCT +Dex)-treated rats (g). Densitometric analysis of the data is shown in (h) with GAPDH used as a loading control. Results represent mean ± SEM of 5
rats per group compared using Student t test. *p< 0.05, **p< 0.01, ***p< 0.001
A: Control rat B: Positive control (nuclease)
C: MCT rat D: MCT + dex-treated rat
100µm
100µm100µm
100µm
E
Fig. 2 Dexamethasone increases apoptosis in pulmonary artery smooth muscle cell (PASMC) layer in monocrotaline (MCT) and
dexamethasone-treated rats. In-situ detection of DNA fragmentation was performed on lung sections from control rats and on lungs
resected from rats 28 days following MCT, with and without dexamethasone treatment (5 mg/kg/day from day 14–28). Representative examples in (a)
a control rat, (b) nuclease-positive cells in an MCT-treated rat (black arrow), (c) negative-stained cells (unfilled arrow) in a rat at day 28 following MCT
and (d) in a rat at day 28 following MCT and dexamethasone treatment (showing positive stained cells, black arrow). Results are representative of n = 5
per group (for a, c and d). Slides are counterstained with eosin. Magnification ×200. Scoring was performed by an assessor blinded to the groups for
percentage positive PASMC over total number of counted cells (e). Results represent mean ± SEM of n = 5 per group, compared using 1-way ANOVA
and Bonferroni’s post-test., *p < 0.05 ***p < 0.001
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Dexamethasone (10−7 M and 10−6 M) increased this 0 %
FCS-induced PASMC apoptosis at 48 and 72 h in a time-
and concentration-dependent manner (Fig. 3f and g). There
was no significant difference in the ability of serum starva-
tion alone and/or dexamethasone treatment to increase
apoptosis in cells from control or day 21-MCT-exposed
rats at 72 h (Fig. 3h).
To confirm these results, we analyzed DNA fragmenta-
tion using an ELISA-based assay. These results also showed
that dexamethasone significantly increased apoptosis in a
time- and concentration-dependent manner in serum-
starved rat PASMC, especially in control cells, reaching a
plateau after 72 h with 10−8 M dexamethasone (p < 0.01)
(Fig. 4a). Dexamethasone increased apoptosis in PASMC
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Fig. 3 Effects of foetal calf serum (FCS) and dexamethasone on apoptosis of cultured control rat PASMC. Representative Hoechst 33342 stained
images from PASMC from control rats treated for 48–72 h with (a) 10 % FCS/DMEM as a negative control, (b) 800nM hydrogen peroxide (H2O2)
as a positive control, (c) 0 % FCS and (d) 0 % FCS plus dexamethasone (10−7 M). Images are representative of 5–8 images per condition from
n = 3–4 independent experiments per group at a magnification ×400. Data from these and other similar experiments inducing apoptosis by treating
cells with dichloroacetate (DCA, 100 μM) and differing concentrations of H2O2 (100-800nM) for 48 h are quantified in (e). The effect of altering
FCS concentrations on dexamethasone-induced apoptosis of PASMC at 48 h are shown graphically in (f) in cells from control rats. (g) The increased
apoptosis observed by culturing cells with FCS and dexamethasone for 72 h rather than 48 h. Similar apoptotic responses to dexamethasone and FCS
are seen in PASMC isolated from control and 21 day MCT-exposed rats (h). Results represent mean ± SEM from n= 3–5 per group, compared using 1-way
ANOVA and Bonferroni’s post-test. *p< 0.05, **p < 0.01, ***p< 0.001
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from control rats and from rats exposed to MCT for
21 days at both 48 and 72 h. There was significantly less
apoptosis induced in cells from MCT-treated rats com-
pared to control rats in terms of absolute values (Fig. 4b
and c). However, when expressed as the proportion of
apoptosis from baseline serum starvation the difference
was no longer significant (Fig. 4d and e).
Effect of dexamethasone on NF-κB and Stat3 activation in
rat pulmonary vascular cells
We have previously shown activation of NF-κB in vascular
cells and macrophages in end-stage human idiopathic PAH
[5]. To determine whether elevation of NF-κB activity also
plays a role in the development of rat MCT-PH, we
performed morphometric analysis of NF-κB p65 in PASMC
and endothelial cells (EC) in lung sections. As shown in
Fig. 5, we observed an increase in nuclear p65 activation in
lung from rats with MCT-induced PH at day 28 compared
to control rats in both PASMC (16.1 ± 2.27 % vs. 55.7 ±
5.02 %, p < 0.001) and EC (15.3 ± 3.46 % vs. 84.4 ±
5.75 %, p < 0.001) (Fig. 5). Nuclear p65 activation was
reduced at day 28 following day 14–28 dexamethasone
treatment of the rats in both PASMC and EC (p < 0.001
for both cell types) at all doses of dexamethasone
Fig. 4 Dexamethasone increases apoptosis in 21 day monocrotaline (MCT)-treated rat pulmonary arterial smooth muscle cells (PASMC). Rat
PASMC were isolated from control rats and from rats 21 days after exposure to MCT and treated with an increasing concentration of dexamethasone
(Dex) and appropriate controls. Apoptosis, as measured by DNA fragmentation, was increased from baseline in serum-starved cells (0 % FCS) in control
PASMC by Dex (10−8–10−6 M) at both 48 h (grey bars) and 72 h (black bars) (a). There was a significant difference between control and MCT-exposed
cells at 48 h (b) and 72 h (c) following 10−7 M and 10−6 M Dex treatment. However this difference was lost when data were normalised to baseline
serum starvation levels at 48 h (d) and 72 h (e). Results represent mean ± SEM from n = 3–5, compared using 1-way ANOVA and Bonferroni’s post-test.
*p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 5 Dexamethasone reduced nuclear p65 expression in lung vascular cells of rats with monocrotaline (MCT)-induced pulmonary hypertension
(PH). Rats with MCT-induced PH were treated with dexamethasone (Dex, 5 mg/kg/day) from day 14–28. Immunohistochemical staining for p65
(brown) was performed on lung sections from rats from untreated controls at day 28 (a) showing p65-ve cells (unfilled arrow). (b) p65 + ve cells
(filled black arrow) were observed in MCT treated rats at day 28. In contrast, p65-ve cells (unfilled arrow) were seen in dexamethasone-treated
MCT-exposed rats (c). An antibody-negative control is shown in slide d. Magnification × 200. Blinded morphometric scoring showed that MCT increased
the percentage of total nuclear p65-positive cells in PASMC (e) and endothelial cells (f). This was reduced in all dexamethasone-treated
groups in a dose-dependent manner. Results represent mean ± SEM of n = 5 per group, compared using Kruskal Wallis and Dunn’s post-test.
*p < 0.01, **p < 0.01, ***p < 0.001
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studied compared to MCT alone (Fig. 5). In addition,
activation of the upstream activator of NF-κB, IKK-α/β,
was increased in EC (although not PASMC) in the MCT-
PH model and reduced by dexamethasone in lung tissue
from the MCT-induced PH study (Fig. 6a–d).
Stat3 was also activated in the remodeled pulmonary
artery (Fig. 6e). No activated phospho-Stat3 (P-Stat3)
staining was observed in the lung from control rats
whereas P-Stat3 was expression was clearly present in
the lung of MCT-treated rats. Interestingly, total Stat3
A B
C
E
D
Fig. 6 Dexamethasone reduces monocrotaline (MCT)-induced enhancement of phospho-IKK-α/β immunostaining in rat lung vascular cells. The expression
of activated phospho-IKKα/β (brown staining) was measured in lung sections from rats from untreated control rats (a); day 28 MCT-treated rats (b) and
MCT and dexamethasone day 14–28-treated rats (c). These data suggest an increase in IKKα/β activation in the EC layer in MCT rats (black arrow)
(b), which was reduced in dexamethasone-treated rats (unfilled arrow) (c). Sections represent n = 2–3 per group (a–c); and were counterstained with
haematoxylin. Antibody-negative control is shown in slide D. Magnification x100 (b, c) and ×200 (a, d). Phospho (P)-Stat3 and Stat3 staining was per-
formed in control, MCT and MCT +Dex rats (n = 3 per group), with SMA staining of smooth muscle actin (bottom panel, magnification x200) (e). The
results show that MCT enhances P-stat3 expression and that this is reduced in the presence of dexamethasone
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staining was also increased in the lungs of MCT-treated
rats. Dexamethasone treatment abolished the MCT-
induced elevation of P-Stat3 expression as well as signifi-
cantly reduced total Stat3 levels (Fig. 6e). Although,
NFAT1 (NFATC2) has been reported to be elevated in
pulmonary artery in the lung from iPAH patients [22],
we were unable to detect NFAT1 in the lung from con-
trol and MCT rats (data not shown). It is possible that
NFAT is not involved in this model or a different NFAT
isoform is elevated in this model.
The effect of dexamethasone and an IKK-2 inhibitor on
IL-6 and CXCL-8 release from human pulmonary artery
smooth muscle cells
We have previously shown in the MCT-induced PH model
that dexamethasone treatment resulted in reversal of
remodeling, and that this was associated with reduced IL-6
activity [19]. We were interested to determine the effect of
dexamethasone and the IKK-2 inhibitor AS602868 on IL-6
production by human PASM cells in vitro. We selected to
use TNF-α as our in vitro stimulus, as this is a well-known
activator of NF-κB [23] as well as being implicated in
PAH [24]. Dexamethasone and AS602868 both caused a
concentration-dependent reduction in TNF-α-stimulated
IL-6 and CXCL8 release from human PASMCs. IL-6 re-
lease was increased from baseline by TNF-α (4962 ± 581
vs 13056 ± 624 pg/ml, p < 0.001) and was reduced in a
concentration-dependent manner by dexamethasone
(10−9–10−6 M, p < 0.001) (Fig. 7a). CXCL-8 release was
similarly increased by TNF-α (866 ± 127 vs 13018 ±
464 pg/ml, p < 0.001) and was reduced in a concentration-
dependent manner by dexamethasone (10−8–10−6 M,
p < 0.001) (Fig. 7b). Although IL-6 and CXCL8 are not
strictly relevant to the study of apoptosis, they are crit-
ical to understanding the importance of inflammation
in PAH and are also useful readouts of NF-κB activity.
Similarly, the increase in IL-6 release by TNF-α
(3450 ± 887 vs 7856 ± 657 pg/ml, p < 0.001) was also
reduced in a concentration-dependent manner by AS6
02868 (0.3–3 μM, p < 0.001) (Fig. 8a). CXCL8 release
was enhanced by TNF-α (702 ± 266 vs 8701 ± 775 pg/ml,
p < 0.001) and again was reduced by AS602868 in a
concentration-dependent manner (0.1–3 μM, p < 0.001)
(Fig. 8b). For all these experiments, PASMC viability was
assessed by MTT and showed no change in cell viability
across all conditions (Figs. 7c and 8c).
Dexamethasone inhibits NF-kB activity in human pulmonary
artery smooth muscle cells
As one of the major mechanisms of action of dexametha-
sone is through inhibition of NF-κB activity, we performed
a TransAM assay to measure NF-κB p65 DNA binding in
nuclear extracts, using a selected single concentration of
dexamethasone (10−7 M). Following TNF-α simulation
there was an increase in NF-κB activity (0.027 ± 0.025 to
0.44 ± 0.022 units, p < 0.001), which was significantly
Fig. 7 Dexamethasone (Dex) reduces interleukin (IL)-6 and CXCL8 release from human pulmonary arterial smooth muscle cells (PASMC). Human
PASMC were plated out at 5000/well in 96-well plates; serum-starved overnight, and treated with tumour necrosis factor (TNF)-α (10 ng/ml) for
24 h in the presence and absence of dexamethasone (10−10–10−6 M) and IL-6 (a) and CXCL8 (b) release into the cell supernatant measured by
ELISA. MTT assays were also performed to assess cell viability (c). Results represent mean ± SEM for n = 4, compared using 1-way ANOVA and
Bonferroni’s post-test analysis. *p < 0.05, ***p < 0.001
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reduced following treatment with 10−7 M dexamethasone
(0.44 ± 0.022 to 0.31 ± 0.062 units, p < 0.01) (Fig. 9). This
would indicate that at least part of the effects of dexa-
methasone in human PASMC is through inhibition of
p65 NF-κB DNA binding but other aspects of the NF-κB
pathway may also be affected.
The effect of IKK-2 inhibition on apoptosis of human
PASMCs
To directly link inhibition of NF-κB with the observed in-
crease in apoptosis seen in rat PASMs in vivo and in vitro,
we investigated the effect of IKK2 inhibition on apoptosis
of human PASMC in vitro. After serum deprivation,
Hoechst staining demonstrated increased human PASMC
apoptosis following IKK2 inhibition (3 μM) from 9.23
(7.43–10.08) % in controls to 20.74 (19.8–21.6) % with
3 μM IKK2 inhibitor (p < 0.001) at 24 h, and from 13.42
(10.8–13.4) % to 26.9 (20.3–34.3) % at 48 h (p < 0.01)
(Fig. 10a-b). A second apoptosis measurement technique
using an ELISA-based assay to detect DNA fragmentation
similarly demonstrated an increase in PASMC apoptosis
following IKK2 inhibition (0.21 ± 0.07 vs. 0.94 ± 0.25,
p < 0.01 at 48 h) (n = 5) (Fig. 10c-d).
Discussion
In this study, using in vivo and in vitro models, we have
shown that the reverse-remodelling effect of dexametha-
sone, previously observed in our MCT-treated rat model
[19], involves, at least in part, increased apoptosis of
Fig. 8 IKK-2 inhibition reduces interleukin (IL)-6 and CXCL8 release from human pulmonary arterial smooth muscle cells (PASMC). Human PASMC
were plated at 5000/well in 96-well plates; starved overnight in FCS-free media and treated with tumour necrosis factor (TNF)-α (10 ng/ml) with
and without the IKK-2 inhibitor AS602868 (0–3 μM) for 24 h. IL-6 (a) and CXCL8 (b) release into the supernatants was measured by ELISA.
MTT assays were also performed to assess cell viability (c). Results represent mean ± SEM for n = 4, compared using 1-way ANOVA and
Bonferroni’s post-test. *p < 0.05, ***p < 0.001
Fig. 9 Dexamethasone (Dex) inhibits tumour necrosis factor
(TNF)-α-induced activation of nuclear factor (NF)-κB in human
pulmonary arterial smooth muscle cells (PASMC). PASMC from 3
healthy human subjects were stimulated with TNF-α (0–10 ng/ml) in
the presence and absence of dexamethasone (Dex, 10−7 M) for 1 h.
NF-κB p65 DNA binding in nuclear extracts was measured by TransAm
assay. Data are reported as the mean ± SEM. *p < 0.05, ***p < 0.001
using Kruskal Wallis and Dunn’s post-test analysis
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PASMC. Furthermore, we show, for the first time, that
dexamethasone treatment caused apoptosis of human
PASMC in vitro as indicated by increased caspase 3 acti-
vation and DNA fragmentation.
Dexamethasone has been previously shown to induce
apoptosis in several immune cells including T and B-
lymphocytes, monocytes, eosinophils [25] and both acti-
vated and non-activated PBMC [26]. In these cells,
dexamethasone-induced apoptosis is thought to play a
homeostatic or immunosuppressive role [27]. Dexa-
methasone also induces apoptosis in non-immune cells
including nasal polyp fibroblasts [28], but generally is
protective against apoptosis in non-immune cells includ-
ing mammary cells, human gastric cancer cells, lung
epithelial cells and hepatoma cells and thereby protects
them from ongoing inflammatory damage [25]. The
pro- or anti-apoptotic effect of dexamethasone is thus
considered cell type-dependent.
Proposed pro-apoptotic mechanisms of dexamethasone
include direct activation of the pro-apoptotic members of
the Bcl-2 family (e.g. Bcl-2, Bad and Bcl-XL [29]; sup-
pression of cell survival factors such as AP-1 [30] or via
interaction of the glucocorticoid receptor with the pro-
apoptotic death-associated protein DAP3 [31]. Alterna-
tively, indirect suppression of anti-apoptotic cytokines
by corticosteroids may cause apoptosis in various cell
types [26] and IL-6, a known proliferative stimulus for
PASMC [32], may be important in our study.
Dexamethasone-induced apoptosis may also vary de-
pending on the stage of the cell cycle. For example in
activated T cells, dexamethasone induced apoptosis in
G0/G1 phase, but not in the proliferative phase [33]. It
would be interesting to further examine the potential
different effects through phases of the cell cycle in
PASMC. Finally, dexamethasone may induce apoptosis
via altered signalling of the key inflammatory transcrip-
tion factor NF-κB [34].
The evidence that inflammation is associated with the
pathogenesis of many types of PAH, including idiopathic
PAH (iPAH) is increasing [35]. Histological specimens
from patients demonstrate peri-vascular inflammatory
infiltrates in subtypes of PAH including CHD [12],
CTD-PAH, portopulmonary PH and more recently in
iPAH patients [7]. These infiltrates involve T cells,
monocytes/macrophages, DC, and, to a lesser extent, B
cells [3, 7, 10–12]. Circulating levels of cytokine and
chemokines are elevated in blood from iPAH patients,
some of which predict worse outcomes [9].
Potential inflammatory pathways co-ordinating this
inflammatory phenotype include the key transcription
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Fig. 10 IKK2 inhibition increases apoptosis of human pulmonary arterial smooth muscle cells (PASMC). Human PASMC were isolated from normal
human lung following surgery and treated with an increasing concentration of the IKK2 inhibitor AS602868 (0–3 μM). Apoptosis as determined
by Hoechst staining was increased from baseline in serum-starved cells (0 % FCS) at 24 h (a) and 48 h (b) (n = 3 for each group). Similar results
were seen when apoptosis was measured at 24 h (c) and 48 h (d) using a DNA fragmentation ELISA (n = 5 for each group). Results represent
mean ± SEM, compared using 1-way ANOVA and Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001
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factor NF-κB. Indeed we demonstrated NF-κB activation
in MCT-treated rat PASMC. NF-κB activation via IKK2
is implicated in a feed-forward inflammatory cascade
involving the induction of key chemokines such as
IL-8/CXCL-8 and cytokines including IL-1, IL-6 and
TNF-α involved in the pathogenesis of iPAH [36, 37]
[38]. Furthermore, recognised triggers of PAH includ-
ing viral infections [39], oxidative stress [40] and
alveolar hypoxia and shear stress [41, 42] are also
activators of NF-κB [36]. Indeed, NF-κB activation
was demonstrated in alveolar macrophages obtained
at bronchoscopy in patients with less severe iPAH
[43]; and in alveolar macrophages, lymphocytes, and
pulmonary endothelial and PASMC in iPAH patients
with severe end stage disease [5]. This would suggest
a role for NF-κB throughout the disease process. Fur-
thermore, constitutive activation of NF-κB has also been
demonstrated in PASMC from patients with heritable
PAH [44]. Finally, NF-κB activation has also been shown
to be a feature of animal models including MCT-
induced and sugen/hypoxia PH in rats [45–47]. Longi-
tudinal studies in MCT-induced PH have documented
NF-κB activation in vascular cells and mononuclear
cells, with evidence for initial p65 nuclear binding
followed by a more persistent reduction in the inhibi-
tory subunit IκB-α from 2 weeks [45, 46].
Anti-inflammatory glucocorticoids have multiple mech-
anisms of action. To exert their anti-inflammatory effects,
glucocorticoids bind the intracellular glucocorticoid re-
ceptor (GR), thereafter to specific DNA sequences (gluco-
corticoid-response elements, GRE) to induce transcription
i.e. transactivation of anti-inflammatory genes, such as
IκBα (the gatekeeper that limits NF-κB migration into the
nucleus) [48]. A second and probably more important
mechanism by which GC suppress inflammation is
through direct GR protein-protein interaction thus inhib-
ition of pro-inflammatory mediators, i.e. transrepression,
as described between GR and p65 [49]. Transrepression
explains the GC-mediated inhibition of many inflamma-
tory cytokines (e.g. IL-6, IL-1β, TNF-α) which all have NF-
κB and/or AP-1 elements in their gene promoter regions
[50], and we demonstrated this as an example in PASMC
with both TNF-induced IL-6 and CXCL8 release reduced
following dexamethasone and NF-κB inhibition. In keep-
ing with these effects, our results show a significant reduc-
tion in nuclear p65 as determined by TransAm assay in
control human PASMC following dexamethasone treat-
ment. However, the effect was small and does not
account for the full effects of dexamethasone reported
here and other down-stream actions of dexamethasone
on NF-κB activation are also likely to be important.
Transrepression of pro-inflammatory transcription factors
is thought to largely explain the clinical success of GC as
effective anti-inflammatory agents whereas transactivation
is thought to contribute to the adverse metabolic effects
of GCs [51].
There is a rationale for blocking NF-κB using dexa-
methasone or specific inhibitors of NF-κB. Indeed, in
some patients with associated inflammatory conditions
including SLE, MCTD and POEMS, treatment of the
underlying condition with immunosuppression including
GC improved pulmonary haemodynamics in PAH [14,
15, 52]; although this has been rarely studied in iPAH to
date [18]. In vitro studies show that GC inhibit prolifer-
ation of human PASMC derived from patients with
iPAH [20] in association with inhibition of G0/G1 to S
phase cell cycle progression, inhibition of PDGF-induced
PASMC migration [20] and reduced NF-κB activation
[53]. Interestingly, other immunosuppressive agents in-
cluding azathioprine, rapamycin and cyclosporin had no
effect on PASMC proliferation [20]. We reproduced this
anti-proliferative effect using dexamethasone in rat
PASMC in association with a reduction in IL-6 and an
increase in BMPRII mRNA [19].
NF-κB inhibition has been shown to exert both anti-
apoptotic and pro-apoptotic effects in different cell types
[34] and we show in this study that an IKK-2 inhibitor
increased apoptosis in human PASMC in vitro. NF-κB
blocks cell death through induction of anti-apoptotic
and antioxidant genes and is an essential ‘survival factor’
for immune cells. Anti-apoptotic NF-κB target genes
include caspase-8-c-FLIP, cellular inhibitors of apoptosis
(c-IAPS), A1 (also known as Bfl1), TNFR-associated fac-
tor 1 (TRAF1), TRAF2. Caspase-8-c-FLIP, cIAPS and
A1, which all act in concert to block multiple steps in
apoptotic signaling [34]. In contrast, NF-κB suppresses
apoptosis in Ras-transformed cells and other tumours.
This is considered a hallmark of cancer and pro-survival
roles for various IKK family members have been re-
ported [54]. Inhibition of NF-κB using the proteasome
inhibitor bortezomib enhanced apoptosis and tumour
regression in response to chemotherapy [55]. Ultimately,
the pro- or anti-apoptotic effects of NF-κB, as with cor-
ticosteroids, are cell and stimulus-specific [54]. That
NF-κB can suppress apoptosis in cancer cell lines is
being explored as a tool in cancer therapies, and could
be of potential relevance to PH where excessive cell
proliferation and reduction in apoptosis has been likened
to a cancer like phenotype [56].
In models of PH, both GC and specific inhibitors of
NF-κB prevent the onset of PH [45, 57–60] and re-
verse established PH, for example in the MCT model
[19, 46]. The reverse-remodelling hypothesis then fits
with our finding that both dexamethasone and IKK2
inhibition increased apoptosis in relevant cells sug-
gesting that inhibition of NF-κB led to a regression of
the pulmonary smooth muscle layer in the in vivo
studies. NF-κB indeed regulates aspects of control of
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cell turnover including apoptosis [61, 62]. Of course
to assess a causal link between inhibition of NF-κB
and an increase in PASMC apoptosis would require
further in-depth studies using transgenic mice and
knockout models. Induction of apoptosis as a reverse-
remodelling approach has been shown in previous
PAH studies investigating nitric oxide [63], dichloroacetate
[64], imatinib [65] and statins [66]. That inhibition of NF-
κB could be augmenting apoptosis in PASMC is relevant
to PAH therapies. In the rat sugen-hypoxia PAH model,
administration of the NF-κB inhibitor pyrrolidine dithio-
carbamate (PDTC) also reduced apoptosis of PASMC and
obliteration of these vessels, promoted immune regulation
(e.g. by increasing perivascular T cells and reducing T lym-
phocytes and CD45RA+ B lymphocytes, while preserving
right ventricular function [47]).
In addition to the pro-apoptotic effect of NF-κB inhib-
ition via direct effects on apoptotic pathways as men-
tioned above, suppression of inflammatory mediator
release may also modulate vascular remodelling. IL-6 is
implicated in human PAH [8, 9] and rodent PH models
[67] [68] and has been shown to be pro-proliferative in
vascular SMC [32]. Hagen et al. identified a regulatory
loop involving IL-6 and BMP signalling, in which upreg-
ulated IL-6 was seen in mice PASMC lacking functional
BMPR-II, and IL-6 administration in vivo increased
BMP pathway activity [69]. Inhibiting IL-6 expression
could, therefore, augment the anti-proliferative ‘damping’
effects of BMP signalling. Furthermore, pulmonary arterial
EC co-treated with IL-6 and MCT in vitro increased pro-
liferation due to enhanced activation of STAT3 [70]. Per-
sistent activation of STAT3 has been shown to reduce
BMPR-II expression [71]. We provide further evidence of
such a regulatory loop here as we show that STAT3 acti-
vation, as measured by phosphorylation and by absolute
levels, increased with MCT treatment but was reversed by
dexamethasone and have previously reported that MCT
and dexamethasone inversely modulate BMPR2 mRNA
expression in this model [19].
In a gastric cancer cell line, IL-6 inhibited apoptosis
through inhibition of JNK signalling and subsequent
cell death [72]. It would therefore be of interest to as-
certain whether, in addition to reducing proliferation,
whether blocking IL-6 could directly augment apop-
tosis in PASMC. It is interesting that a recent study
by Farkas et al., inhibiting IL-6 with an anti-IL-6 anti-
body had a lesser effect on PASMC apoptosis than
using PDTC to inhibit NF-κB [47], suggesting this ap-
proach is likely to be more beneficial than focusing
on a single pathway.
Limitations
We were limited by not performing all analyses on human
PASMC, and it would be ideal to do this on PASMC
isolated from patients. This is however difficult as the only
available lung samples are from patients with end-stage
pulmonary hypertension following transplantation or
death. We therefore extrapolated findings from PASMC
isolated from healthy lung. We did not include a dexa-
methasone alone arm within the in vivo study, and so the
effects of dexamethasone on baseline hemodynamics and
vascular remodeling is unknown.
Summary
We showed by several methods that in rat and human
PASMC, dexamethasone and specific inhibition of NF-κB
increased PASMC apoptosis, and reduced IL-6 and CXCL8
release from these cells. In human PASMC, dexamethasone
reduced p65 nuclear import and/or DNA binding as
measured by TransAm assay. These results suggest that
dexamethasone exerted anti-remodeling effects on PASMC
in the rat MCT PH model through an induction of apop-
tosis in these cells, which is likely to be through NF-κB
inhibition. Which NF-κB signalling pathway components,
and whether related to a reduction in IL-6 and CXCL8
signaling, requires further study.
Clinical implications
The anti-remodelling effects of dexamethasone in the
MCT model provide a rationale for clinical trials using
GC and/or NF-κB inhibitors in patients with PAH
including iPAH. That IKK-2 inhibition exerted similar
effects as dexamethasone on cytokine release and pro-
apoptotic effects, at least in control human cells, is en-
couraging as these agents are likely to have less systemic
side effects than GC, although they may potentially lead
to opportunistic infections due to suppression of the
innate immune system with chronic treatment.
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